1-(4-甲氧基苯基)-2-(甲基氨基)乙醇 | 58777-87-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(4-甲氧基苯基)-2-(甲基氨基)乙醇
• 英文名称: 1-(4-methoxyphenyl)-2-methylamino-1-ethanol
• 英文别名: 1-(4-methoxyphenyl)-2-(methylamino)ethanol；1-(4-methoxyphenyl)-2-(methylamino)ethan-1-ol；longimammine；(+/-)-Longimammin；(+/-)-1-(4-Methoxy-phenyl)-2-methylamino-aethanol；2-methylamino-1-(p-methoxyphenyl)ethanol
• CAS: 58777-87-0
• 化学式: C₁₀H₁₅NO₂
• 分子量: 181.235
• InChiKey: IWLPVZQFUJSAKT-UHFFFAOYSA-N

物化性质

• 稳定性/保质期：

  避免接触氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2922509090
• 储存条件：
  在密封的贮藏器中，并将其存放在阴凉、干燥处避光保存。

反应信息

• 作为反应物：
  描述：

  1-(4-甲氧基苯基)-2-(甲基氨基)乙醇 在 溶剂黄146 、 sodium nitrite 作用下， 以 水 为溶剂， 生成 2-methylamino-N-nitroso-1-(p-methoxyphenyl)ethanol
  参考文献：
  名称：

  Synthesis, in Vitro Activity, and Three-Dimensional Quantitative Structure−Activity Relationship of Novel Hydrazine Inhibitors of Human Vascular Adhesion Protein-1

  摘要：

  Vascular adhesion protein-1 (VAP-1) belongs to the semicarbazide-sensitive amine oxidases (SSAOs) that convert amines into aldehydes. SSAOs are distinct from the mammalian monoamine oxidases (MAOs), but their substrate specificities are partly overlapping. VAP-1 has been proposed as a target for anti-inflammatory drug therapy because of its role in leukocyte adhesion to endothelium. Here, we describe the synthesis and in vitro activities of novel series of VAP-1 selective inhibitors. In addition, the molecular dynamics simulations performed for VAP-1 reveal that the movements of Met211, Ser496, and especially Leu469 can enlarge the ligand-binding pocket, allowing larger ligands than those seen in the crystal structures to bind. Combining the data from molecular dynamics simulations, docking, and in vitro measurements, the three-dimensional quantitative structure-activity relationship (3D QSAR) models for VAP-1 (q(LOO)(2): 0.636; r(2:) 0.828) and MAOs (q(LOO)(2): 0.749, r(2): 0.840) were built and employed in the development of selective VAP-1 inhibitors.

  DOI：

  10.1021/jm100337z
• 作为产物：
  描述：

  p-Methoxy-N-methyl-mandelsaeureamid 在 四氢呋喃 、 lithium aluminium tetrahydride 作用下， 生成 1-(4-甲氧基苯基)-2-(甲基氨基)乙醇
  参考文献：
  名称：

  Pratesi et al., Farmaco, Edizione Scientifica, 1957, vol. 12, p. 993,1001

  摘要：

  DOI：

文献信息

• Asymmetric Hydrogenation of α-Primary and Secondary Amino Ketones: Efficient Asymmetric Syntheses of (−)-Arbutamine and (−)-Denopamine
  作者：Gao Shang、Duan Liu、Scott E. Allen、Qin Yang、Xumu Zhang

  DOI：10.1002/chem.200700594

  日期：2007.9.17

  Two beta-receptor agonists (-)-denopamine and (-)-arbutamine were prepared in good yields and enantioselectivities by asymmetric hydrogenation of unprotected amino ketones for the first time by using Rh catalysts bearing electron-donating phosphine ligands. A series of alpha-primary and secondary amino ketones were synthesized and hydrogenated to produce various 1,2-amino alcohols in good yields and

  通过使用带有给电子膦配体的Rh催化剂进行不保护的氨基酮的不对称氢化，以高收率和对映选择性制备了两种β受体激动剂（-）-地巴胺和（-）-arbutamine。合成了一系列的α-伯氨基和仲氨基酮并进行氢化，以高收率和良好的对映选择性生产出各种1,2-氨基醇。这种Rh电子给体的膦催化的不对称氢化反应代表了手性氨基醇不对称合成的最有希望和最方便的方法之一。
• Antiviral agents
  申请人：——

  公开号：US20040138449A1

  公开（公告）日：2004-07-15

  The invention provides a compound of formula I: 1 wherein G, R 2 , and R 3 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of treating a herpesvirus infection using such compounds or salts.

  本发明提供了一种公式I的化合物： 1 其中G，R 2 ，和R 3 具有规范中定义的任何值，或其药用可接受盐，以及用于制备该化合物或盐的有用过程和中间体，以及使用该化合物或盐治疗疱疹病毒感染的方法。
• Design and Scalable Synthesis of <i>N</i> ‐Alkylhydroxylamine Reagents for the Direct Iron‐Catalyzed Installation of Medicinally Relevant Amines**
  作者：Eric Falk、Szabolcs Makai、Tristan Delcaillau、Laura Gürtler、Bill Morandi

  DOI：10.1002/anie.202008247

  日期：2020.11.16

  and other biologically active small molecules. Herein, we report their direct synthesis from alkenes through an aminative difunctionalization reaction enabled by iron catalysis. A family of ten novel hydroxylamine‐derived aminating reagents were designed for the installation of several medicinally relevant amine groups, such as methylamine, morpholine and piperazine, through the aminochlorination of

  仲和叔烷基胺是特权物质类别，通常在药物和其他具有生物活性的小分子中发现。在本文中，我们报道了它们通过铁催化的胺化双官能化反应从烯烃直接合成。设计了十种新颖的羟胺衍生胺化试剂家族，用于通过烯烃的氨基氯化来安装几个与医学相关的胺基，例如甲胺，吗啉和哌嗪。该方法具有出色的官能团耐受性，并且将宽范围的烯烃转化为相应的产物，包括几种药物样分子。除了氨基氯化以外，还可以通过氨基叠氮化，氨基羟基化甚至分子内碳氨基化反应来安装其他功能，
• α-Aminated methyllithium by DTBB-catalysed lithiation of a N-(chloromethyl) carbamate
  作者：Javier Ortiz、Albert Guijarro、Miguel Yus

  DOI：10.1016/s0040-4020(99)00155-6

  日期：1999.4

  The reaction of O-tert-butyl-N-(chloromethyl)-N-methyl carbamate (1) with lithium powder and a catalytic amount of 4,4′-di-tert-butylbiphenyl (DTBB, 2.5 mol %) in the presence of different electrophiles [Me3SiCl, iBuCHO, tBuCHO, PhCHO, 4-MeOC6H4CHO, (CH2)4CO, MeCOnPr, Et2CO, MeCO(CH2)2CHCH2, PhCOMe, PhCOnBu, Ph2CO] in THF at −78°C leads, after hydrolysis with water, to the expected functionalised

  的反应ö -叔丁基- ñ - - （氯甲基）ñ -甲基氨基甲酸叔丁酯（1与锂粉末和）催化量的4,4'-二-叔在存在-butylbiphenyl（DTBB，2.5摩尔％）不同的亲电子的[我3的SiCl，我BuCHO，吨BuCHO，苯甲醛，4-MeOC 6 H ^ 4 CHO，（CH 2）4 CO，梅科ñ PR等2 CO，梅科（CH 2）2 CHCH 2， PhCOMe，PhCO n Bu，Ph 2在-78°C下的THF中，CO]用水水解后，生成预期的官能化氨基甲酸酯2。衍生自羰基化合物的氨基甲酸酯2用氯化氢（对于芳香族醛或酮衍生物）或与苯酚和三甲基甲硅烷基氯的混合物（对于脂肪族醛衍生物）脱保护，得到取代的1,2-二醇4。
• [EN] PYRIMIDINE DERIVATIVES AS OREXIN RECEPTORS ANTAGONISTS<br/>[FR] DERIVES DE PYRIMIDINE UTILISES EN TANT QU'ANTAGONISTES DE RECEPTEURS D'OREXINE
  申请人：SANOFI AVENTIS

  公开号：WO2005075458A1

  公开（公告）日：2005-08-18

  The present invention relates to the orexin receptor antagonists of the general formula (I), which are selective to orexin I receptors. (I) -wherein Ar stands for phenyl group or a 5- or 6-membered heterocyclic ring containing 1-3 identical or different heteroatoms or methylenedioxyphenyl group -these groups may optionally be substituted with one or more identical or different C1.4 alkyl group, halogen atom, hydroxyl group, C1-4 alkoxy group, trihalogenomethyl group, NHC1.4 alkyl, -N(CI-4 alkyl)2 or -NHC(=0)-C1-4 alkyl group,

  本发明涉及通式（I）的俄利新受体拮抗剂，这些拮抗剂对俄利新I受体具有选择性。其中，Ar代表苯基或含有1-3个相同或不同杂原子或亚甲二氧基苯基的5-或6元杂环的环，这些基团可以选择性地用一个或多个相同或不同的C1.4烷基基团、卤原子、羟基、C1-4烷氧基、三卤甲基基团、NHC1.4烷基、-N(CI-4烷基)2或-NHC(=0)-C1-4烷基基团取代。

表征谱图